February 19, 2021 – Over the past few months, numerous healthcare and life sciences organizations have turned to executive search firms to find new leaders. In the era of COVID-19, the sector has been a burgeoning area for executive search firms to ply their trade. Recently, life sciences-focused search firm Slone Partners placed Will Geist as chief operating officer at Quanterix Corp. “Will is an extraordinarily talented and accomplished executive with an impressive track record of success in operations, sales, marketing and business development leadership roles,” said Leslie Loveless, CEO of Slone Partners. “He will be a welcome addition to the very strong Quanterix executive team at an important time in the company’s evolution.”
“Quanterix is experiencing strong momentum across numerous digital biomarker platforms supporting drug development and non-invasive, early disease diagnostics research,” said Kevin Hrusovsky, chairman, president and CEO of Quanterix. “We are fortunate to attract Will into Quanterix at this important time given his wealth of operating experience and track record for growing revenue and profitability, both commercially and operationally.” Mr. Geist brings more than 25 years of experience to Quanterix, most recently serving as vice president and general manager for two of Thermo Fisher Scientific’s largest business units – Protein and Cell Analysis (PCA), and qPCR. He also served a key leadership role in Thermo Fisher Scientific’s biosciences division COVID-19 task force. Prior to joining Thermo Fisher Scientific, Mr. Geist held several other top leadership titles, including vice president of sales, marketing and business development At QIAGEN’s Quanta BioSciences.
In his new role, Mr. Geist will build on Quanterix’s track record of strong execution as the company expands globally and continues to disrupt pharmaceutical development and diagnostics research. “I am very excited to join Quanterix during this phase of growth and expansion,” said Mr. Geist. “I have long admired the company’s mission and welcome the opportunity to further operationalize and scale the innovation that Quanterix continues to achieve as part of its vision for precision health.”
Founded in 2007, Quanterix is digitizing biomarker analysis with the goal of advancing the science of precision health. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population.
Slone Partners is a nationally recognized senior-level recruitment provider that specializes in delivering executive, management and leadership talent for the diagnostic, biopharmaceutical, healthcare information technology and laboratory testing industries. The firm has offices in Boston, New York, Washington, D.C., and San Francisco. Recently, the firm was included among Hunt Scanlon Media’s “Top 50 Healthcare & Life Sciences Search Firms.”
Slone Partners Recruits CEO for Mesa Biotech
The race is on to find a vaccine for COVID-19 – and along with it the pace is picking up to find top leadership talent at many of the nation’s leading life sciences, medical diagnostics and biotech companies. Here’s one of the latest searches just successfully completed.
Ms. Loveless has deep knowledge of the healthcare arena, with nearly 20 years of experience in both the industry itself and recruitment. She had been with Slone Partners for nine years, including a stint as chief operating officer, when she became CEO in 2016. Her role as leader of the firm’s executive search team, meanwhile, keeps her perpetually involved with clients and candidates and the daily workings of the firm.
The firm recently placed Mike Spigarelli as chief medical officer of Lumen Bioscience in Seattle, WA. “As an extremely skilled industry leader with three decades of medical, pharmaceutical and academic experience, Mike Spigarelli has a thorough understanding of clinical affairs, drug development and regulatory strategy,” said Ms. Kochis-Stach, of Slone Partners. “He will be a tremendously valuable addition to the Lumen Bio executive team at a time when the company is advancing a number of exciting new investigational biologic drugs.”
Contributed by Scott A. Scanlon, Editor-in-Chief; Dale M. Zupsansky, Managing Editor; and Stephen Sawicki, Managing Editor – Hunt Scanlon Media